Suppr超能文献

具有抗泪液蛋白吸附和眼科疾病持续药物递送功能的聚(甲基丙烯酸2-羟乙酯)/β-环糊精-透明质酸隐形眼镜

Poly(2-hydroxyethyl methacrylate)/β-cyclodextrin-hyaluronan contact lens with tear protein adsorption resistance and sustained drug delivery for ophthalmic diseases.

作者信息

Li Ruicong, Guan Xipeng, Lin Xilin, Guan Pengyue, Zhang Xiong, Rao Zhouquan, Du Lin, Zhao Jiafeng, Rong Jianhua, Zhao Jianhao

机构信息

Department of Materials Science and Engineering, College of Chemistry and Materials Science, Jinan University, Guangzhou 510632, China.

Guangzhou Yuexin Biomedical Technology Co., Ltd, Guangzhou 510001, China.

出版信息

Acta Biomater. 2020 Jul 1;110:105-118. doi: 10.1016/j.actbio.2020.04.002. Epub 2020 Apr 24.

Abstract

A series of poly(2-hydroxyethyl methacrylate) (pHEMA) hydrogels containing cross-linked β-cyclodextrin-hyaluronan (β-CD-crHA), with tear protein adsorption resistance and sustained drug delivery, were developed as contact lens materials for eye diseases. β-CD-HA was synthesized from aminated β-CD and HA and then crosslinked within pHEMA hydrogel using polyethylenimine as a crosslinker. The synthesized β-CD-HA was characterized by H NMR analysis, and β-CD-crHA immobilized in pHEMA hydrogel was confirmed by FT-IR, SEM, and AFM analyses. The incorporation of β-CD-crHA significantly improved the surface hydrophilicity, water uptake ability, oxygen permeability, and flexibility of pHEMA hydrogel, but did not compromise light transmission. pHEMA/β-CD-crHA hydrogels not only decreased the tear protein adsorption because of the electrostatically mutual repulsion and the improved hydrophilicity, leading to the reduced adhesion of Staphylococcus aureus on the hydrogel surface, but also enhanced the encapsulation capacity and the sustainable delivery of diclofenac due to the formation of inclusion complexes between β-CD and drugs. All the hydrogels were nontoxic to 3T3 mouse fibroblasts by in vitro cell viability analysis. Among these hydrogels with different β-CD-crHA contents, pHEMA/β-CD-crHA hydrogel showed the lowest water contact angle of 52 °, the highest water content of 65%, the largest Dk value of 36.4 barrer, and the optimal modulus of 1.8 MPa, as well as a good light transmission of over 90%. The in vivo conjunctivitis treatment of rabbits for 72 h indicated that drug-loaded pHEMA/β-CD-crHA hydrogel presented a better therapeutic effect than both one dose administration of drug solution per day and drug-loaded pHEMA hydrogel. Thus, pHEMA/β-CD-crHA hydrogel is a promising contact lens material for ophthalmic diseases. STATEMENT OF SIGNIFICANCE: Topical eye drops are currently the most popular treatment for ophthalmic diseases, but frequent dosing is necessary to acquire the desirable clinical effect at the expense of systemic side-effects. Drug-loaded contact lenses, as an alternative of eye drops, possess many good performances and show potential applications. However, the sustained drug delivery and the tear protein adsorption resistance are still challenging for contact lenses. Hence, we developed a novel pHEMA/β-CD-crHA hydrogel by incorporating β-CD-crHA crosslinked network into pHEMA hydrogel. Besides the improvements in surface hydrophilicity, water uptake ability, oxygen permeability, and flexibility, pHEMA/β-CD-crHA hydrogel also reduced the adsorption of tear proteins and the adhesion of Staphylococcus aureus, enhanced the drug encapsulation, and prolonged the drug delivery, with better effect in the conjunctivitis treatment of rabbits. Thus, pHEMA/β-CD-crHA hydrogel is a potential contact lens material for treating ophthalmic diseases.

摘要

开发了一系列含有交联β-环糊精-透明质酸(β-CD-crHA)的聚甲基丙烯酸2-羟乙酯(pHEMA)水凝胶,其具有抗泪液蛋白吸附和持续药物递送的特性,作为用于眼部疾病的隐形眼镜材料。β-CD-HA由胺化β-环糊精和透明质酸合成,然后使用聚乙烯亚胺作为交联剂在pHEMA水凝胶中交联。通过1H NMR分析对合成的β-CD-HA进行表征,并通过FT-IR、SEM和AFM分析确认固定在pHEMA水凝胶中的β-CD-crHA。β-CD-crHA的加入显著提高了pHEMA水凝胶的表面亲水性、吸水能力、透氧性和柔韧性,但不影响透光率。pHEMA/β-CD-crHA水凝胶不仅由于静电相互排斥和改善的亲水性而降低了泪液蛋白吸附,导致金黄色葡萄球菌在水凝胶表面的粘附减少,而且由于β-CD与药物之间形成包合物而增强了双氯芬酸的包封能力和持续递送。通过体外细胞活力分析,所有水凝胶对3T3小鼠成纤维细胞均无毒。在这些具有不同β-CD-crHA含量的水凝胶中,pHEMA/β-CD-crHA水凝胶的水接触角最低,为52°,水含量最高,为65%,最大Dk值为36.4巴耳,最佳模量为1.8MPa,透光率也超过90%。对兔进行72小时的体内结膜炎治疗表明,载药pHEMA/β-CD-crHA水凝胶比每天一剂给药的药物溶液和载药pHEMA水凝胶均具有更好的治疗效果。因此,pHEMA/β-CD-crHA水凝胶是一种有前途的用于眼科疾病的隐形眼镜材料。

重要意义声明

局部眼药水是目前治疗眼科疾病最常用的方法,但为了获得理想的临床效果需要频繁给药,这会带来全身副作用。载药隐形眼镜作为眼药水的替代品,具有许多良好的性能并显示出潜在的应用。然而,持续药物递送和抗泪液蛋白吸附对隐形眼镜来说仍然具有挑战性。因此,我们通过将β-CD-crHA交联网络引入pHEMA水凝胶中,开发了一种新型的pHEMA/β-CD-crHA水凝胶。除了表面亲水性、吸水能力、透氧性和柔韧性的改善外,pHEMA/β-CD-crHA水凝胶还减少了泪液蛋白的吸附和金黄色葡萄球菌的粘附,增强了药物包封,并延长了药物递送,在兔结膜炎治疗中效果更好。因此,pHEMA/β-CD-crHA水凝胶是一种治疗眼科疾病的潜在隐形眼镜材料。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验